Clinical trial · Observational
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases
NCT02518698CI-TRIAL-00034915completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radium-223 dichloride (Xofigo, BAY88-8223) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort 1 / Treatment patterns
- description
- Patients with castrated resistant prostate cancer and bone metastases
- interventionNames
- Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
Primary outcomes (10)
- measure
- Overall survival of mCRPC patients
- timeFrame
- Up to 24 months
- description
- mCRPC: Metastatic castrate-resistant prostate cancer
- measure
- Number of skeletal related events (SREs) of the mCRPC patients
- timeFrame
- Up to 30 months
- measure
- Type of skeletal related events (SREs) of the mCRPC patients
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 55 Years
- Maximum age
- 88 Years
Show eligibility criteria text
Inclusion Criteria: * First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period * Members age ≥ 55 to 89 years at index * Medicare members with medical and pharmacy coverage; and * Continuously enrolled during the pre- and post-index periods. Exclusion Criteria: * Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and * Members age ≥ 89 years of age at index date
References
Publications (0)
Data not yet available
No reference posted for this study.